From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

BioFuture 2026 Convenes Industry Leaders in New York City to Explore the Trends Reshaping Biopharma and Healthcare

Next Wave of Innovation: Navigating Policy and Regulatory Headwinds, featuring Cartier Esham, Esham Strategies; Jennifer Hawks Bland, NewYorkBIO; William Soliman, ACMA; Blake Wilson, Hogan Lovells Cadwalader; and Susan Winckler, Reagan-Udall Foundation, moderated by Lori Ellis, Open Door Salon.

FDA Plans Cannabis Public Health Messaging Initiative With Consumer and Healthcare Provider Testing

FDA intends to award a sole-source contract to the Reagan-Udall Foundation for the FDA to carry out 16 regulatory science and public health projects, including a dedicated project titled “Cannabis Public Health Message Testing.”

Spruce Biosciences at H.C. Wainwright: BLA Path Comes into Focus

The regulatory picture changed in February 2024, when the FDA held a Reagan-Udall Foundation forum on neuronopathic mucopolysaccharidoses.

Why CDC Opioid Guidelines Get the Overdose Data Wrong

On Wednesday, September 9, 2026, the author spoke briefly at a hybrid conference conducted by the Reagan-Udall Foundation for the U.S. Food and Drug Administration in Washington, D.C.

This Week at FDA: Pregnancy Exposure Registries, PRV Fee Rates, and More

The Reagan-Udall Foundation for the FDA and FDA are also co-hosting a hybrid meeting on 16 October to discuss where the patient voice is needed in the rare disease product development timeline, its impact, and opportunities for patients to engage in the product development process.

Regan-Udall Foundation Report Provides Recommendations Related to Infant Formula Safety

The Reagan-Udall Foundation recently released a report summarizing lessons learned following investigations into 2025 and 2026 infant formula recalls due to the presence of Clostridium botulinum (C. botulinum).

Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule

This month the Reagan-Udall Foundation published Applying the Science of Infant Formula Safety, a report on a July 13 roundtable convened with, and funded by, ByHeart and the International Dairy Foods Association.

Rischio di C. botulinum nelle Infant Formula

L’americana Reagan-Udall Foundation for the FDA (Fondazione) ha pubblicato un report che delinea una tabella di marcia basata su basi scientifiche per l’industria, i governi e i partner accademici al fine di affrontare il rischio di Clostridium botulinum nel latte artificiale in polvere per neonati.

Recommendations from Industry-Led Reagan-Udall Roundtable on Controlling C. botulinum in Infant Formula

Following two unprecedented infant botulism outbreaks linked to ByHeart- and Nara Organics-brand powdered infant formula in 2025–2026, a new report from the Reagan-Udall Foundation has outlined recommendations intended to advance scientific understanding of Clostridium botulinum risks and strengthen controls throughout the infant formula supply chain.

ByHeart and the Dairy Industry Paid for a Report on the Formula Botulism Outbreaks. It Has 22 Recommendations, No Parent in the Room, and No Rule

The Reagan-Udall Foundation for the FDA has published Applying the Science of Infant Formula Safety, a 44-page report on a July 13, 2026 roundtable about Clostridium botulinum in powdered infant formula.